Equities
Health CarePharmaceuticals & Biotechnology
  • Price (USD)158.49
  • Today's Change-2.43 / -1.51%
  • Shares traded460.18k
  • 1 Year change26.68%
  • Beta0.9097
Data delayed at least 15 minutes, as of Jan 24 2020 20:14 GMT.
More ▼

Profile data is unavailable for this security.

About the company

IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

  • Revenue in USD (TTM)10.88bn
  • Net income in USD236.00m
  • Incorporated2016
  • Employees58.00k
  • Location
    IQVIA Holdings Inc4820 Emperor BlvdDURHAM 27703-8426United StatesUSA
  • Phone+1 (919) 998-2000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.iqvia.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
IQV:NYQ since
announced
Transaction
value
Corezetta Co LtdRumoured19 Mar 201919 Mar 2019Rumoured10.77%--
Novasyte LLCDeal completed12 Mar 201912 Mar 2019Deal completed13.68%--
Linguamatics LtdDeal completed31 Jan 201931 Jan 2019Deal completed24.24%72.14m
Data delayed at least 15 minutes, as of Jan 24 2020 20:14 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cardinal Health Inc147.66bn-4.15bn16.05bn49.50k--17.86--0.1087-14.05-14.05495.093.073.7311.2918.152,983,071.00-10.482.60-24.716.024.645.16-2.810.72680.49926.640.898559.416.389.83300.443.225.679.50
Incyte Corporation2.11bn404.96m16.85bn1.37k41.976.9636.618.001.861.869.7111.250.735113.018.061,541,896.0014.12-1.9116.70-2.3395.8896.4419.21-2.445.01--0.0205--22.5039.60134.97--76.69--
AmerisourceBergen Corp.179.59bn818.37m18.77bn22.00k23.716.5514.380.10453.844.02843.5413.924.6715.2014.458,163,142.002.132.118.538.732.782.780.4550.44350.577112.960.600243.626.948.48-21.7523.773.2411.22
Seattle Genetics, Inc.801.42m-304.29m19.77bn1.30k--11.09--24.67-1.87-1.874.9310.400.43730.80874.68615,531.50-16.60-16.85-18.87-20.5991.5688.47-37.97-31.444.49-4.910.00--35.7619.45-77.40---0.8587--
McKesson Corporation221.98bn-674.00m27.95bn80.00k--4.3158.350.1259-3.75-3.541,172.9536.013.6912.7311.622,774,763.00-0.76073.15-2.228.615.335.75-0.20630.91350.56532.060.503615.382.869.3093.42--6.0610.66
Iqvia Holdings Inc10.88bn236.00m31.22bn58.00k137.285.0921.442.871.171.2154.0531.600.4794--4.52187,603.501.212.151.442.6634.3732.042.523.61--1.990.64350.007.3215.35-27.97-0.229839.04--
Regeneron Pharmaceuticals Inc7.62bn2.09bn38.49bn7.40k19.593.7216.835.0518.2118.6966.4295.740.6160.74593.131,029,959.0016.8817.7419.3720.7592.2192.9127.4023.683.5125.230.06350.0014.2826.1055.8641.1419.63--
Data as of Jan 24 2020. Currency figures normalised to IQVIA Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

33.78%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 201919.82m10.21%
BlackRock Fund Advisorsas of 30 Sep 20199.16m4.72%
SSgA Funds Management, Inc.as of 30 Sep 20197.34m3.78%
Fidelity Management & Research Co.as of 30 Sep 20195.44m2.80%
Jackson Square Partners LLCas of 30 Sep 20195.36m2.77%
Canada Pension Plan Investment Boardas of 30 Sep 20194.09m2.11%
Janus Capital Management LLCas of 30 Sep 20193.70m1.91%
Glenview Capital Management LLCas of 30 Sep 20193.62m1.86%
Lone Pine Capital LLCas of 30 Sep 20193.55m1.83%
Capital Research & Management Co. (Global Investors)as of 30 Sep 20193.46m1.78%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.